Saniona Dirección

Dirección controles de criterios 3/4

El CEO de Saniona es Thomas Feldthus , nombrado en Apr 2022, tiene una permanencia de 2.58 años. compensación anual total es SEK3.98M, compuesta por 60.7% salario y 39.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.25% de las acciones de la empresa, por valor de €353.66K. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 8 años, respectivamente.

Información clave

Thomas Feldthus

Chief Executive Officer (CEO)

SEK 4.0m

Compensación total

Porcentaje del salario del CEO	60.7%
Permanencia del CEO	2.6yrs
Participación del CEO	1.3%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Thomas Feldthus en comparación con los beneficios de Saniona?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-SEK 82m
Mar 31 2024	n/a	n/a	-SEK 83m
Dec 31 2023	n/a	n/a	-SEK 96m
Sep 30 2023	n/a	n/a	-SEK 108m
Jun 30 2023	n/a	n/a	-SEK 33m
Mar 31 2023	n/a	n/a	-SEK 100m
Dec 31 2022	SEK 3m	SEK 1m	-SEK 212m
Sep 30 2022	n/a	n/a	-SEK 334m
Jun 30 2022	n/a	n/a	-SEK 445m
Mar 31 2022	n/a	n/a	-SEK 461m
Dec 31 2021	n/a	n/a	-SEK 411m
Sep 30 2021	n/a	n/a	-SEK 326m
Jun 30 2021	n/a	n/a	-SEK 280m
Mar 31 2021	n/a	n/a	-SEK 200m
Dec 31 2020	n/a	n/a	-SEK 73m
Sep 30 2020	n/a	n/a	-SEK 25m
Jun 30 2020	n/a	n/a	-SEK 5m
Mar 31 2020	n/a	n/a	-SEK 751k
Dec 31 2019	SEK 2m	SEK 2m	-SEK 69m
Sep 30 2019	n/a	n/a	-SEK 96m
Jun 30 2019	n/a	n/a	-SEK 53m
Mar 31 2019	n/a	n/a	-SEK 52m
Dec 31 2018	SEK 2m	SEK 2m	-SEK 41m
Sep 30 2018	n/a	n/a	-SEK 32m
Jun 30 2018	n/a	n/a	-SEK 61m
Mar 31 2018	n/a	n/a	-SEK 56m
Dec 31 2017	SEK 2m	SEK 2m	-SEK 49m

Compensación vs. Mercado: La compensación total ($USD360.49K) de Thomas está en línea con el promedio de empresas de tamaño similar en el mercado German ($USD471.14K).

Compensación vs. Ingresos: La compensación de Thomas ha aumentado mientras la empresa no es rentable.

CEO

Thomas Feldthus (64 yo)

2.6yrs

Permanencia

SEK 3,981,000

Compensación

Mr. Thomas Feldthus, M.Sc., MBA, served as Independent Director at Scandion Oncology A/S since 2018 until May 25, 2022. He serves as Chief Executive Officer at Saniona AB (publ) since April 30, 2022. He co...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jorgen Drejer	Founder	10.8yrs	SEK 412.00k	2.29% € 647.9k
Thomas Feldthus	Co-Founder & CEO	2.6yrs	SEK 3.98m	1.25% € 353.7k
Anita Milland	Chief Financial Officer	2.6yrs	sin datos	0.030% € 8.5k
Karin Nielsen	Chief Scientific Officer	8.7yrs	sin datos	0.19% € 53.3k
Palle Christophersen	Executive Vice President of Research	2.8yrs	SEK 1.38m	0.70% € 196.7k
Janus Larsen	Chief Development Officer	2.8yrs	sin datos	0.26% € 72.6k

2.8yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 30S se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jorgen Drejer	Founder	10.8yrs	SEK 412.00k	2.29% € 647.9k
Carl Sundberg	Independent Director	9.2yrs	SEK 430.00k	0.13% € 37.1k
Anna Ljung	Independent Director	6.8yrs	SEK 496.00k	0.0086% € 2.4k
Pierandrea Muglia	Independent Director	1.5yrs	SEK 117.00k	0.18% € 52.2k

8.0yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de 30S se considera experimentada (8 años de antigüedad promedio).

Saniona Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Saniona AB (publ), Annual General Meeting, May 29, 2024

Saniona AB Appoints Nomination Committee for the Annual General Meeting 2023

Insufficient new directors

Insufficient new directors

Saniona Appoints Anita Milland as Chief Financial Officer, Effective April 30, 2022

Saniona Announces Management Appointments

Recent updates

Saniona Initiates SAN711 Biomarker Study

Saniona Receives Regulatory Approval for San711 Biomarker Study

New major risk - Financial position

Second quarter 2024 earnings released: kr0.18 loss per share (vs kr0.34 loss in 2Q 2023)

New major risk - Share price stability

First quarter 2024 earnings released: kr0.08 loss per share (vs kr0.35 loss in 1Q 2023)

Saniona AB (publ) to Report Fiscal Year 2023 Results on Apr 30, 2024

New major risk - Negative shareholders equity

Full year 2023 earnings released: kr1.49 loss per share (vs kr3.93 loss in FY 2022)

Saniona Announces the Selection of Its Proprietary GABAA A5 Negative Allosteric Modulator (NAM) Lead Compound, San2465

Saniona AB (publ) Strengthens Epilepsy Pipeline with Selection of SAN2355 as Clinical Candidate

Third quarter 2023 earnings released: kr0.38 loss per share (vs kr0.28 profit in 3Q 2022)

Saniona AB (publ) to Report Fiscal Year 2024 Results on Feb 27, 2025

Saniona AB (publ), Annual General Meeting, May 29, 2024

Saniona Promotes Kv7 Epilepsy Compound to Candidate Selection Phase

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr1.42 loss in 2Q 2022)

New minor risk - Shareholder dilution

First quarter 2023 earnings released: kr0.35 loss per share (vs kr2.14 loss in 1Q 2022)

Full year 2022 earnings released: kr3.93 loss per share (vs kr6.59 loss in FY 2021)

Saniona AB Appoints Nomination Committee for the Annual General Meeting 2023

Third quarter 2022 earnings released: EPS: kr0.28 (vs kr1.50 loss in 3Q 2021)

Saniona AB (publ) to Report Q1, 2023 Results on May 25, 2023

Insufficient new directors

Saniona AB (publ) Announces Anti-Inflammatory and Anti-Fibrotic Candidate SAN903 Is Ready for Clinical Studies

Second quarter 2022 earnings released: kr1.42 loss per share (vs kr1.67 loss in 2Q 2021)

Saniona Progresses Its Kv7 Epilepsy Program into Lead Optimization

Saniona Reports Positive Top Line Results from the SAN711 Phase 1 Clinical Trial

Insufficient new directors

Saniona’S Preclinical Candidate San903 Shows Robust Dampening of Fibrosis in Chronic Kidney Disease Model

Saniona Provides Update on Ongoing Review of Tesofensine in Mexico

Saniona Appoints Anita Milland as Chief Financial Officer, Effective April 30, 2022

Saniona Announces Voluntary Pause of Phase 2B Clinical Trials of Tesomet for Hypothalamic Obesity and Prader-Willi Syndrome

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Saniona AB (publ) to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1 Clinical Trial

Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome

Third quarter 2021 earnings released: kr1.50 loss per share (vs kr1.24 loss in 3Q 2020)

Second quarter 2021 earnings released: kr1.67 loss per share (vs kr1.24 loss in 2Q 2020)

Saniona Initiates Phase 1 Clinical Trial of SAN711

Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology

First quarter 2021 earnings released: kr1.34 loss per share (vs kr1.47 profit in 1Q 2020)

Full year 2020 earnings released: kr1.79 loss per share (vs kr2.95 loss in FY 2019)

Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity

Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Prader-Willi Syndrome

New 90-day low: €1.81

Novartis AG (SWX:NOVN) completed the acquisition of Cadent Therapeutics, Inc. from a group of sellers.

New 90-day low: €1.97

Saniona Announces Management Appointments

Co-Founder recently bought €11k worth of stock

New 90-day low: €2.07

Third quarter 2020 earnings released: kr1.24 loss per share

Third quarter 2020 earnings released: kr1.24 loss per share

Saniona AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Saniona AB (publ) Appoints Nomination Committee Members

Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity

New 90-day low: €2.37

Saniona Receives Pre-IND Feedback from FDA on Regulatory Path for Tesomet in Prader-Willi Syndrome (PWS) and Hypothalamic Obesity (HO)

Earnings released

Saniona AB (publ) has completed a Follow-on Equity Offering in the amount of $64.999993 million.

New 90-day high - €3.69

An unknown buyer acquired 3.96% stake in Scandion Oncology A/S (NGM:SCOL) from Saniona AB (publ) (OM:SANION) for for $2.3 million.

New 90-day high - €2.83

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media